Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Inclusion Criteria: * Adult subjects with advanced MDS requiring treatment with HMA and either refractory to at least 4 cycles or progressing after previously documented response * Patient must be treated within 6 months of the last HMA treatment and must be willing to be treated with the same agent they last received on this study * Prior treatment with novel HMA analog of decitabine on clinical trial is allowed; in such cases, decitabine will be used as the standard of care agent * MDS classified as intermediate 1-risk or high risk according to the international prognostic scoring system (IPSS) or revised-IPSS * Chronic myelomonocytic leukemia (CMML) * Acute myeloblastic leukemia (AML) that was previously treated with HMA and is unfit for intensive chemotherapy * Patient must be within 6 months of prior treatment with HMA and must be willing to be treated with the same agent on this study * During the 8 weeks prior to inclusion in study, subjects must have a baseline bone marrow examination including all of the following: * Cytomorphology to confirm bone marrow blasts * Cytogenetics * Eastern Cooperative Oncology Group (ECOG) status 0-2 * Subject is able to understand and willing to comply with protocol requirements and instructions * Subject has signed and dated informed consent * Total bilirubin (except for Gilbert's syndrome) =\< 2.5 x upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN * Creatinine …